Advertisement

Lower limb superficial venous ablation: Does “tumescentless” axial treatment have a future?

Published:November 23, 2022DOI:https://doi.org/10.1016/j.ejvs.2022.11.016
      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Vascular and Endovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Linked Article

      • Plasma extracellular vesicle SerpinG1 and CD14 levels are associated with MACE and MALE in patients undergoing femoral endarterectomy
        European Journal of Vascular and Endovascular Surgery
        • Preview
          Plasma extracellular vesicles (EV) are an emerging source of biomarkers for diagnosis and prognosis of cardiovascular disease (CVD). Risk stratification for common adverse events such as Major Adverse Limb Event (MALE) and Major Adverse Cardiovascular Events (MACE) by an EV blood sample could improve healthcare management by individualizing drug therapy or by improving informed decision-making regarding revascularisations in patients with PAD. As such, we investigated the associations of plasma EV proteins with prospectively registered MALE and MACE in consecutive patients undergoing femoral endarterectomy.
        • Full-Text
        • PDF